🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “furmonertinib” Clear

  1. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  2. furmonertinib 240 mg oral, daily

    ArriVent BioPharma

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Furmonertinib

    Peking University People's Hospital

    Adenocarcinoma of Lung

    phase 2 small molecule active

    1 trial

  4. Furmonertinib

    Shanghai University of Traditional Chinese Medicine

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  5. Furmonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  6. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  8. furmonertinib

    Sun Yat-sen University

    Non-small Cell Lung Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  9. A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

    phase 1 other active

    1 trial

  10. Furmonertinib

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources